We studied the protective effects of Qingyi decoction (QYD) (a Traditional Chinese Medicine) against severe acute pancreatitis (SAP)-induced myocardial infarction (MI).
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open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licen ses/by-nc/4.0/ Manuscript source: Unsolicited manuscript INTRODUCTION Severe acute pancreatitis (SAP) is one of the most common types of acute abdominal inflammatory diseases, with approximately 20% of new cases reported annually. SAP can lead to multiple organ dysfunction syndromes (MODS), such as SAP-induced myocardial injury (MI), which is associated with an approximate 10%-30% mortality rate among SAP patients [1] [2] [3] . Globally, the SAP mortality rate ranges between 15%-30%, while in China the rate is 11.8%-16.6% [4] . SAP is characterized by sudden onset of severe persistent upper abdominal pain, which is epigastric and radiates towards the back. SAP results from pathological dysfunction of the pancreatic microcirculation, which leads to pancreatic vascular thrombosis and reduced pancreatic blood flow [5] . Without prompt intervention, SAP progresses rapidly, leading to irreversible multiple organ damage and early death [6] [7] [8] .
MI is a predominant complication of SAP-induced MODS [9, 10] . Synchronized manifestations of myocardial dysfunction [11] , such as abnormal electrocardiography, troponin imbalance, myocardium abnormalities, altered cardiac input/output ratio, arrhythmia, cardiac shock, myocarditis, pericarditis, and other types of MIs, have been reported in SAP patients [6, 7, 12] . Chinese herbs and Traditional Chinese Medicine (TCM) have long been used in China to treat various diseases [8, [13] [14] [15] [16] [17] [18] [19] [20] . Qingyi decoction (QYD), a TCM that includes several medicinal plants and minerals (Supplementary Table 1 ), has been used to treat acute pancreatitis in animal models.
QYD can cause purgation, promote hemostasis, and stimulate anti-inflammatory 
responses. Moreover, the role of QYD was illustrated in our previous study using an acute pancreatitis model, in which we reported that QYD reduced lung injury and protected pulmonary function [7, 8, 16] . Previous studies have also shown that QYD regulates the immune response in the gut. Specifically, QYD controls intestinal cell electrical activity by maintaining smooth muscle physiological function and directly neutralizing endotoxins that protect the intestinal barrier [5, 9, 10, 12, 13, 21, 22] . Our previous studies demonstrated that QYD protects against acute pancreatitis by suppressing G protein-coupled bile acid receptor 1 expression, subsequently inhibiting caspase-9 activation. Furthermore, QYD blocked the NF-kb/p-RIP inflammatory signaling pathway in an in vitro acute pancreatitis model, demonstrating a beneficial effect by decreasing apoptosis of alveolar type II epithelial cells in a SAP rat model [11, 23] . Moreover, Su et al [24] and Zhang et al [6] showed that QYD can ameliorate intestinal barrier damage by inhibiting overexpression of secretory phospholipase A (sPLA2) and Toll-like receptor 4, and increasing occludin-1 expression in a SAP rat model. Recent studies demonstrated that QYD can attenuate SAP-induced MI [12, 21, 22] .
Microvascular endothelial cell apoptosis is controlled by the store-operated calcium entry (SOCE) associated proteins STIM1 and Orai1, by regulating intracellular calcium ion concentration; however, calcium flux is closely associated with cardiac cell damage [1] [2] [3] 14] . Based on these findings, we hypothesized that QYD protects against SAP-induced MI via the STMI1/Orai1-SOCE pathway, resulting in regulation of cell apoptosis and pathogenesis.
MATERIALS AND METHODS

Animal model
Forty adult healthy male Sprague-Dawley (SD) rats, weighing between 180-220 g, were obtained from the Specific Pathogen Free Animal Department of Dalian Medical University (Dalian, China), and the study protocol followed the ethical guidelines approved by the Dalian Medical University Animal Care and Use Committee. The rats were randomly divided into four groups (n = 10 per group): (1) Healthy control (Sham); (2) SAP; (3) 2-aminoethyl diphenyl borinate (2-APB), which is a STIM1/Orai1-SOCE pathway inhibitor; and (4) QYD treatment.
The SAP model was induced by injecting 5% sodium taurocholate. Briefly, animals were fasted for 12 h with free access to water before surgery. Rats were anesthetized with 1% pentobarbital sodium anesthesia (intraperitoneal injection, 40 mg/100 g body weight) prior to surgery. A midline incision was made in the rat abdomen, and the pancreatic bile duct was identified. Sodium taurocholate 5% (1 mL/kg, cat no: T4009; Sigma-Aldrich, St. Louis, MO, United States) was retrogradely injected into the distal end of the pancreatic bile duct at a rate of 0.2 mL/min using a 1 mL syringe and 28gauge needle. The injector needle was opened in the bile duct through the bile ductduodenal connection, avoiding damage to the bile duct. The artery was clamped to prevent injecting the drug into the liver [13] .
Following the establishment of SAP, rats in the QYD group received three doses of QYD orally (1 mL/100 g body mass): One dose immediately after SAP induction (0 h), then one after 12 h and 24 h, respectively [13] . The Sham group received no intervention, while the SOCE inhibitor group received 2-APB (2 mg/kg body mass) orally immediately after SAP induction. The Sham group only received laparotomy and subsequent exposure of the duodenum and was given the same treatment as the SAP group but with phosphate buffered saline (PBS). The rats were then placed in suitable living conditions with only free access to water. After 24 h, mortality and morbidity were monitored. The rats were anesthetized with 1% pentobarbital sodium anesthesia (intraperitoneal injection, 40 mg/100 g body weight) before sacrifice by ex-sanguination, and heart tissues and blood specimens were harvested under sterile conditions for analyses.
Echocardiography assessment of cardiac function
Transthoracic echocardiography assessment of left ventricular (LV) function was conducted 24 h after SAP induction and prior to euthanizing the rats. Heart function measurements were performed using the GE Logiq E9 ultrasound system with a probe (ML6-15-D). Cardiac function was assessed by a sonographer to determine changes in cardiac muscle function under 10% CH anesthesia. M-mode images of LV dimensions were obtained from the LV ejection fraction (LVEF %) and LV fractional shortening (LVFS %), as previously described, to distinguish cardiac function from myocardial infarction. Data were analyzed by a cardiologist blinded to the study.
Hematoxylin and eosin staining
To evaluate morphological alterations in the myocardial tissue, rats were euthanized 24 h post-treatment and the LV myocardial tissues were collected and fixed in 10% formalin, processed, and embedded in paraffin wax. Thin sections (3-5 μm) were cut and mounted on microscopy slides. The sections were deparaffinized in xylene solution, rehydrated in decreasing serial dilutions of ethanol, and stained with hematoxylin for 10 min, washed with running tap water, decolorized for 3 s with 1% acid, stained with eosin for 1 min, washed with water, and left to air dry. The sections were covered with coverslips and a professional pathologist, who was blinded to the experimental design, examined the slides under a light microscope at a magnification of 40 ×.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) was used to estimate the concentrations of inflammatory cytokines, including interleukin (IL) IL-1ß, IL-6, IL-8, IL-12, tumor necrosis factor alpha (TNF-α), and amyloid β (AMY), in rat serum. Serum samples were incubated at room temperature for a maximum of one hour before assaying. Protein concentrations were measured twice using rat IL-1ß, IL-6, IL-8, IL-12, TNF-α, and AMY ELISA kits (Cusabio Biotech, China) according to the manufacturer's instructions. Measurements were recorded using a spectrophotometer (Thermo Scientific, United States) at 450 nm.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) was performed on the tissue sections to assess apoptosis. Tissue sections were treated with 50 µL of the TUNEL reaction mixture and incubated in a humidified atmosphere for 60 min at 37 °C in the dark, and then rinsed with PBS (pH 7.4) three times, for 5 min each time, followed by 5 min staining with DAPI at room temperature, three 5 min PBS washes, and observed using fluorescence microscopy. The TUNEL-positive cells were marked by yellow/brown nuclei, whereas negative cells stained blue. The apoptotic index was calculated as the percent of TUNEL-positive nuclei relative to the total number of nuclei.
qRT-PCR
To determine STIM1 and Orai1 gene expression, total mRNA was extracted from the LV myocardial tissues from all groups using the TRIzol reagent (Invitrogen, United States) according to the manufacturer's protocol. mRNA (500 ng) from each group was added to the super mix SYPR green II 5× reagents and DNA remover for cDNA synthesis (Transgene Biotech, China). A total volume of 20 μL was placed in the thermocycler (Bio-Rad, Singapore) and PCR was conducted at 42 °C for 15 min and then 85 °C for 5 s. Gene amplification conditions were: 94 °C for 30 s, 94 °C for 5 s, 55°C for 15 s, and 72 °C for 10 s for 45 cycles. MXP/CXP software (Agilent Technologies, Germany) was used to analyze the PCR output, and GAPDH served as the internal control. The Ct 2ΔΔ-CT method was used to calculate the relative mRNA expression of the different genes [25] . The primer sequences are listed in Table 1 .
Protein extraction and quantification
LV tissue was frozen in liquid nitrogen and then crushed for total protein extraction. Radio-Immune Precipitation Assay lysis buffer containing Dithiothreitol, Phenyl Methane Sulfonyl Fluoride and 100 × antiprotease (Roche, China) was used for total protein extraction, according to the manufacturer's protocol. Protein concentrations were estimated using the Bicinchoninic acid assay kit (Thermo Scientific, United States) and standard bovine serum albumin. Protein concentration was quantified using a spectrophotometer (Thermo Scientific, United States) at 594 nm.
Western blot
Western blot analysis was used to measure STIM1 and Orai1 protein expression in the LV myocardial tissues. Equal concentrations of proteins were separated according to their molecular weight using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred onto 0.02 mm polyvinylidene fluoride membranes (Millipore, United States), and blocked with 5% low-fat silk milk (Claix, France) for 3 h at room temperature. The membranes were subsequently incubated with STIM1 monoclonal rabbit anti-rat primary antibody (1:2500; Abcam, United States), Orai1 monoclonal rabbit anti-rat primary antibody (1:2500; Abcam, United States), and GAPDH polyclonal antibody (1:1000; Proteintech, United States) overnight at 4°C. Polyvinylidene fluoride membranes were washed thrice in Trisbuffered saline with Tween 20 and incubated with goat anti-rabbit secondary antibodies (1:1000; LI-COR, United States). Protein bands were detected using a LI-COR scanner (LI-COR, United States). Tris-buffered saline with Tween 20 was used for all antibody dilutions. Quantification of protein expression was achieved using Image J software (International Institute of Health, United States).
Immunohistochemistry
Immunohistochemistry (IHC) was performed to determine the expression and location of STIM1 and Orai1 in the LV myocardial tissues. Tissue sections were prepared as described above for HE staining. The sections were hydrolyzed by placing them in three changes of xylene for 3 min each time, followed by washes in decreasing ethanol concentrations for 2 min per wash. Proteins were retrieved by heating the slides in citrate buffer (pH 6.0) in a microwave for 20 min. The tissues were then incubated in 3% H 2 O 2 for 10 min at room temperature, followed by incubation in the blocking reagent (A) in the IHC kit (ZSGB-BIO, China) for 25 min at room temperature. The tissues were then incubated with STIM1 and Orai1 monoclonal rabbit anti-rat primary antibodies (1:2500; Abcam, United States) overnight at 4 °C, and then washed three times with cold PBS, for 5 min each time. The secondary antibody (B) in the IHC kit (ZSGB-BIO, China) was applied to the tissues for 30 min at room temperature, followed by washing with cold PBS three times, for 5 min each time. Subsequently, the tissues were treated with labeling reagent (C) in the IHC kit (ZSGB-BIO, China) for 30 min at 37 °C. Lastly, diaminobenzidine (ZSGB-BIO, China) was applied at room temperature for 1 min for protein visualization. The tissues were serially dehydrated in diluted alcohol and xylene and air-dried. Coverslips were mounted on the tissue sections and examined under a light microscope at a magnification of 40 ×.
Statistical analysis
SPSS version 17 (IBM, United States) and Graph Pad Prism version 6 (Graph Pad Software Inc., United States) statistical analysis software were used to analyze the data. Survival rates were calculated using an unpaired t-test. ANOVA and the t-test were used to compare differences between groups. Data are presented as mean ± SE. Statistical significance was set at P < 0.05.
RESULTS
QYD treatment reduces SAP-induced MI associated morbidity and mortality
The general condition of the rats was monitored 24 h after SAP induction and treatment. The Sham group appeared healthy, with no mortalities or abnormalities observed. The SAP group demonstrated several signs of abnormalities, including paralysis, laziness, depression, lack of responsiveness, and shortness of breath. We observed 40% (n = 4) mortality in the SAP group (Table 2 ). The QYD group showed significantly fewer signs of morbidity compared to the SAP group, and the survival rate was 90% (Table 2) . Similarly, the 2-APB group exhibited less morbidity and significantly higher survival rates (Table 2 ). These observations suggest that QYD treatment reduces SAP-induced morbidity and mortality.
QYD treatment restores physiological heart function
Rats in all groups were subjected to echocardiography assessment 24 h after SAP induction and before euthanasia. LV circumferential strain measurements were assessed to determine physiological myocardial functions (Figure 1 ). As expected, cardiac function in the SAP group was lower compared to the Sham, QYD, and 2-APB groups ( Figure 1A) . QYD treatment significantly improved LVEF and LV fractional shortening compared to the Sham and the 2-APB groups, suggesting that QYD mitigated SAP-induced MI (Figure 1B and C) . 
QYD treatment reverses myocardial tissue damage and improves immunity in the SAP rat model
To evaluate tissue damage caused by SAP, LV myocardial sections were stained with HE and examined by a blinded professional pathologist. The Sham group showed intact heart muscles without any signs of inflammation or necrosis. In contrast, the SAP group showed increased tissue necrosis, with an increased number of inflammatory cells infiltrating the cardiac muscle, leading to reduced myocardial fiber structures and damage to the myocardial membrane ( Figure 2 ). QYD treatment markedly reduced the alterations in histological morphology in the SAP group (Figure 2 ). We measured protein expression of selected inflammatory cytokines to determine the effect of QYD on the immune response following SAP induction. As shown in Supplementary Figure 1 and Table 3 , ELISA assays revealed that the serum levels of IL-1ß, IL-6, IL-8, IL-12, AMY, and TNF-α were markedly elevated in the SAP group compared to the Sham, QYD, and 2-APB groups. There were no significant differences in protein concentrations between the QYD and 2-APB groups. Thus, QYD treatment can inhibit the SAP-induced inflammatory response.
QYD treatment reduces SAP-induced ventricular myocardial tissue apoptosis
The TUNEL assay was performed to investigate the effect of QYD treatment on myocardial cell apoptosis following SAP (Figure 3) . We counted the number of apoptotic cells (brown/yellow) and total cells (blue) and then calculated the apoptotic index [(apoptotic cell number/total cell number) × 100%] in all groups. The majority of myocardial cells in the Sham group stained blue, and only a few exhibited brown/yellow staining (Figure 3 ). However, a significant number of myocardial cells in the SAP group exhibited brown/yellow staining (P < 0.0001) ( Figure 3 , Table 4 ), indicating increased apoptosis. Although the number of cells with brown/yellow staining in the QYD group was higher compared to the Sham group, the numbers of apoptotic cells in the QYD and 2-APB groups were significantly lower compared to the SAP group (Figure 3 , Table 4 ). As shown in Table 4 , the apoptosis index in the SAP group was significantly higher compared to the Sham group (P < 0.0001). These results suggest that QYD treatment reduces SAP-induced myocardial cell apoptosis.
QYD treatment attenuates SAP-induced MI via the STIM1/Orai1-SOCE pathway
The STIM1/Orai1-SOCE pathway plays a significant role in regulating cell Ca +2 concentrations (Graph 1) and modulating cardiac function. We therefore examined the cardio-protective effects of QYD by assaying its impact on the STIM1/Orai1-SOCE pathway. As 2-APB is a known inhibitor of the STIM1/Orai1-SOCE pathway, we used this inhibitor as a comparative control. Following treatment, expression of STIM1 and Orai1 was measured using RT-PCR, western blot, and IHC. Both QYD and 2APB significantly decreased the SAP-induced increase in myocardial cell STIM1 and Orai1 gene and protein expression (Figure 4 and Supplementary Figure 2) . These observations indicate that the STIM1/Orai1-SOCE pathway is activated following SAP, and that QYD treatment can mitigate SAP-induced activation of the STIM1/Orai1-SOCE pathway, conferring cardio-protection.
DISCUSSION
The goal of this study was to investigate whether the TCM QYD can protect against SAP-induced MI in a rat model. We found that QYD was able to protect against tissue damage, as well as reduce the inflammatory response and cell apoptosis. We further determined that QYD confers cardio-protection by regulating the STIM1/Orai1-SOCE pathway. These findings indicate that QYD could be used clinically to protect again 
SAP-induced MI and subsequent MODS.
Our results further support the literature showing that SAP can induce MI and mortality. We reported only 40% survival following SAP induction in our rat model. However, QYD treatment reduced the SAP-induced MI and lowered the mortality rate by 30%. This finding is similar to that reported for other TCM decoction subtypes (Lai Fu Cheng Qi decoction), which have also demonstrated roles in protecting against lung and intestinal injuries [13, 16, 19, 26] . Collectively, these findings support the development of QYD and similar TCM decoctions as therapeutic approaches to prevent SAP-induced MI.
Our findings also revealed that QYD improves the overall morphological appearance of myocardial tissue following SAP. QYD decreased the myocardial histological abnormalities and infiltration of inflammatory cells caused by SAPinduced MI. QYD also attenuated myocardial cell apoptosis, enhanced cardiac functions, and partially restored the heart muscle. These results support our recently published work [27] [28] [29] [30] .
In this study, we showed that QYD treatment decreased the SAP-induced inflammatory response. Specifically, we found that both QYD and the SOCS inhibitor 2-APB significantly decreased the SAP-induced increase in an array of cytokines AMY, . These results parallel previous findings for 2-APB [5] [6] [7] 31] . Our data indicate that QYD can boost the immune response to SAP, and may therefore have preventive and therapeutic value for treating MI consistent with previous reports [17, 20, 32, 33] .
We further investigated the underlying mechanism by which QYD confers cardioprotection. Specifically, we determined the effect of QYD on the STIM1/Orai1-SOCE pathway (Graph 1). Our gene and protein expression analyses revealed that SAP increased STIM1 and Orai1 expression. These findings reflect the role of the STIM1/Orai1-SOCE pathway in SAP-induced MI. However, QYD treatment reduced the expression of STIM1 and Orai1, suggesting that QYD can stabilize Ca 2+ ion flux and promote myocardial recovery, decrease cell inflammation and necrosis, and preserve cardiac function, consistent with previous studies that targeted the STIM1/Orai1-SOCE pathway [3, 9, 10, 34] . Thus, QYD treatment could play a double role in preventing and preserving myocardial function by targeting the STIM1/Orai1-SOCE pathway.
One challenge in this study was our SAP experimental model; only a few rats survived SAP, limiting the number of rats that could be used for overall analyses.
In summary, QYD confers cardio-protection in response to SAP by controlling immune cytokine levels and cardiac tissue apoptosis by regulating the STIM1/Orai1-SOCE pathway. Further studies are needed to determine the specific mechanism by which QYD modulates Ca +2 flux in myocardial cells. Values are expressed as the mean ± SE (n = 10 for each group). a shows significant difference (P ≤ 0.05) between sham group and the indicated group; b shows significant difference (P ≤ 0.05) between severe acute pancreatitis group and the indicated group; c shows significant difference (P ≤ 0.05) between 2-aminoethyl diphenylborinate group and the indicated group. SAP: Severe acute pancreatitis; QYD: Qingyi decoction; 2-APB: 2-Aminoethyl diphenylborinate; STIM1: Stromal interaction molecule 1; ORAI1: Calcium release-activated calcium channel protein 1.
ARTICLE HIGHLIGHTS
Research background
Severe acute pancreatitis (SAP) is a common acute abdominal inflammatory disease which can lead to multiple organ dysfunction syndromes including myocardial dysfunction. Qingyi decoction (QYD), a Traditional Chinese Medicine, has been used to treat acute pancreatitis in animal models. Previously we reported that QYD reduced lung injury and protected pulmonary function in patients with SAP.
Research motivation
The protective functions of Qingyi decoction against myocardial injuries induced by SAP will provide new therapeutic information on SAP.
Research objectives
To study the function and mechanism of QYD in the treatment of myocardial injuries induced by SAP.
Research methods
We established a SAP model with Sprague-Dawley rats. Echocardiography was performed to assess cardiac function before the rats were euthanized. After euthanizing, hematoxylin and eosin staining of myocardial tissue was performed. Enzyme-linked immunosorbent assay was used to estimate the concentrations of inflammatory cytokines. Terminal deoxynucleotidyl transferase dUTP nick-end labeling was carried out to assess apoptosis. Real-time PCR was used to determine STIM1 and Orai1 gene expression. STIM1 and Orai1 protein expression was analyzed by Western blot. Immunohistochemistry was used to determine the location of STIM1 and Orai1 in myocardial tissue.
Research results
In the present study, our SAP model shows that QYD treatment effectively reduces SAP-induced myocardial injury (MI) associated morbidity and mortality. QYD treatment restores physiological heart function and reverses myocardial tissue damage and improves immunity in the SAP rat model. Our study shows that the STIM1/Orai1-SOCE pathway is mitigated by QYD treatment.
Research conclusions
QYD treatment is able to play a double role as a preventive and curative agent for myocardial injuries induced by acute severe pancreatitis via the STIM1/Orai1-SOCE pathway.
